Switch theme
Sign up to access all valuation multiples
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum revenue from the Bausch + Lomb segment.
1994
20.7K+
LTM Revenue $9.9B
LTM EBITDA $3.4B
$22.0B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Bausch Health has a last 12-month revenue (LTM) of $9.9B and a last 12-month EBITDA of $3.4B.
In the most recent fiscal year, Bausch Health achieved revenue of $6.9B and an EBITDA of $2.0B.
Bausch Health expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Bausch Health valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $9.9B | XXX | $6.9B | XXX | XXX | XXX |
| Gross Profit | $7.1B | XXX | $4.9B | XXX | XXX | XXX |
| Gross Margin | 72% | XXX | 71% | XXX | XXX | XXX |
| EBITDA | $3.4B | XXX | $2.0B | XXX | XXX | XXX |
| EBITDA Margin | 35% | XXX | 29% | XXX | XXX | XXX |
| EBIT | $3.2B | XXX | $1.3B | XXX | XXX | XXX |
| EBIT Margin | 33% | XXX | 19% | XXX | XXX | XXX |
| Net Profit | $1.5B | XXX | -$33.2M | XXX | XXX | XXX |
| Net Margin | 15% | XXX | 0% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $14.8B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Bausch Health's stock price is CAD 6 (or $4).
Bausch Health has current market cap of CAD 2.3B (or $1.7B), and EV of CAD 30.5B (or $22.0B).
See Bausch Health trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $22.0B | $1.7B | XXX | XXX | XXX | XXX | $4.06 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Bausch Health has market cap of $1.7B and EV of $22.0B.
Bausch Health's trades at 3.2x EV/Revenue multiple, and 10.8x EV/EBITDA.
Equity research analysts estimate Bausch Health's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Bausch Health has a P/E ratio of 1.1x.
See valuation multiples for Bausch Health and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.7B | XXX | $1.7B | XXX | XXX | XXX |
| EV (current) | $22.0B | XXX | $22.0B | XXX | XXX | XXX |
| EV/Revenue | 2.2x | XXX | 3.2x | XXX | XXX | XXX |
| EV/EBITDA | 6.4x | XXX | 10.8x | XXX | XXX | XXX |
| EV/EBIT | 6.8x | XXX | 16.5x | XXX | XXX | XXX |
| EV/Gross Profit | 3.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | 1.1x | XXX | -50.0x | XXX | XXX | XXX |
| EV/FCF | 17.9x | XXX | 24.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBausch Health's last 12 month revenue growth is 2%
Bausch Health's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.2M for the same period.
Bausch Health's rule of 40 is 27% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Bausch Health's rule of X is 40% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Bausch Health and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 2% | XXX | 22% | XXX | XXX | XXX |
| EBITDA Margin | 35% | XXX | 29% | XXX | XXX | XXX |
| EBITDA Growth | 3% | XXX | 48% | XXX | XXX | XXX |
| Rule of 40 | 27% | XXX | 31% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 40% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 6% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 52% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Bausch Health acquired XXX companies to date.
Last acquisition by Bausch Health was XXXXXXXX, XXXXX XXXXX XXXXXX . Bausch Health acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Bausch Health founded? | Bausch Health was founded in 1994. |
| Where is Bausch Health headquartered? | Bausch Health is headquartered in Canada. |
| How many employees does Bausch Health have? | As of today, Bausch Health has 20.7K+ employees. |
| Who is the CEO of Bausch Health? | Bausch Health's CEO is Mr. Thomas J. Appio. |
| Is Bausch Health publicy listed? | Yes, Bausch Health is a public company listed on TSE. |
| What is the stock symbol of Bausch Health? | Bausch Health trades under BHC ticker. |
| When did Bausch Health go public? | Bausch Health went public in 1987. |
| Who are competitors of Bausch Health? | Similar companies to Bausch Health include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Bausch Health? | Bausch Health's current market cap is $1.7B |
| What is the current revenue of Bausch Health? | Bausch Health's last 12 months revenue is $9.9B. |
| What is the current revenue growth of Bausch Health? | Bausch Health revenue growth (NTM/LTM) is 2%. |
| What is the current EV/Revenue multiple of Bausch Health? | Current revenue multiple of Bausch Health is 2.2x. |
| Is Bausch Health profitable? | Yes, Bausch Health is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Bausch Health? | Bausch Health's last 12 months EBITDA is $3.4B. |
| What is Bausch Health's EBITDA margin? | Bausch Health's last 12 months EBITDA margin is 35%. |
| What is the current EV/EBITDA multiple of Bausch Health? | Current EBITDA multiple of Bausch Health is 6.4x. |
| What is the current FCF of Bausch Health? | Bausch Health's last 12 months FCF is $1.2B. |
| What is Bausch Health's FCF margin? | Bausch Health's last 12 months FCF margin is 12%. |
| What is the current EV/FCF multiple of Bausch Health? | Current FCF multiple of Bausch Health is 17.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
